BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Pancreatitis FGF21 replacement therapy or inhibition of PERK-mediated FGF21 repression could treat pancreatitis. Pancreatic levels of FGF21 protein were lower in 52 patients with acute or chronic pancreatitis than in 14...
BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

The first ever platform trial in ALS provides a recipe for getting these collaborative studies off the ground quickly and with early buy-in from companies. Platform trials take advantage of a master protocol to test...
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
BC Innovations | Nov 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium In vitro and mouse studies identified an inhibitor of C. difficile TcdB that could help treat C. difficile infection (CDI). Chemical synthesis and in vitro testing of hexakisphosphate analogs of inositol yielded a...
BC Week In Review | Sep 7, 2018
Company News

Biohaven gets rights to AZ's myeloperoxidase inhibitor

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted the Biohaven Therapeutics Ltd. subsidiary of Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) exclusive, worldwide development and commercialization rights to BHV3241 (AZD3241). Biohaven has rights to all indications except cardiovascular disease....
BC Innovations | May 9, 2018
Distillery Therapeutics

Gastrointestinal

INDICATION: Pancreatitis Mouse studies suggest PIEZO1 inhibition could help treat pancreatitis. In a mouse model of pressure-induced acute pancreatitis, pancreatic acinar cell-specific knockout of PIEZO1 or the PIEZO1 inhibitor AT-300 decreased histological disease scores and...
BC Innovations | Mar 28, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on MPO could help predict the risk of colorectal cancer and predict survival in patients. Genotyping of 1,277 colorectal cancer patients and 1,175 unaffected individuals from the Chinese population identified an...
BC Innovations | Aug 29, 2017
Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting DPP-4 could help treat colitis. In a mouse model of colitis, intracolonic administration of a peptide inhibitor of DPP-4 decreased macroscopic colon damage and ulcer scores,...
BC Innovations | Apr 25, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest the cucurbitane analog mogroside IIIE and other TLR4 inhibitors could help treat pulmonary fibrosis. In primary lung fibroblasts from a mouse model of the disease, mogroside IIIE decreased fibroblast...
Items per page:
1 - 10 of 42